Public procurement notice: Prior Information Notice Without Call For Competition
Published: 2018-01-12
Buyer: NHS Supply Chain acting as agent for NHS Business Services Authority
Country: UK
Contract type: Supplies
CPV classification: 31711140 | 33100000 | 33124100 | 33124130 | 33140000: Medical consumables
Estimated value: 280000000 GBP

Technical requirements: Neuromodulation Devices Consumables and associated Products including Intrathecal Drug Delivery Pumps
Non-exclusive framework agreement for the supply to the NHS Supply Chain customer base via the E-Direct Route. Product range to include, but not limited to:
However, NHSSC may be interested in capturing other procedures or products that potential suppliers may consider relevant to the overarching requirement for devices, consumables and other products that are associated with neuromodulation procedures.
Precise quantities are unknown. It is anticipated that initial expenditure will be in the region of £30m to £52m in the first year of this FAG; however, this is approximate only and the values may vary depending on the requirements of those bodies purchasing under the FAG. The estimated value over the total FAG term (including any extension options) is £280m.
Deep brain stimulation is a neurosurgical procedure involving the implantation of a medical device called a neurostimulator, which sends electrical impulses through implanted electrodes to specific targets in the brain for the treatment of movement and neuropsychiatric disorders. This surgery benefits patients with the following symptons: Parkinson's disease, essential tremor, dystonia, chronic pain, major depression, obsessive–compulsive disorder and others. Deep brain stimulation directly changes brain activity in a controlled manner, its effects are reversible. The deep brain stimulation system consists of three components: the implanted pulse generator (IPG), the lead and an extension.
Precise quantities are unknown. It is anticipated that initial expenditure will be in the region of £9,500,000 to £11,500,000 in the first year of this framework agreement; however, this is approximate only and the values may vary depending on the requirements of those bodies purchasing under the framework agreement.
Sacral nerve stimulation typically involves the implantation of a programmable stimulator subcutaneously, which delivers low amplitude electrical stimulation via a lead to the sacral nerve, usually accessed via the S3 foramen. In the event that the nerves and the brain are no longer communicating effectively, resulting in a bowel/bladder disorder, this type of treatment is designed to imitate a signal sent via the central nervous system. The sacral nerve stimulation system consists of three components: the implanted pulse generator (IPG), the lead, and patient remote.
Precise quantities are unknown. It is anticipated that initial expenditure will be in the region of £8,000,000 to £10,000,000 in the first year of this framework agreement; however, this is approximate only and the values may vary depending on the requirements of those bodies purchasing under the framework agreement.
Spinal cord stimulator or dorsal column stimulator is a type of implantable neuromodulation device that is used to send electrical signals to select areas of the spinal cord (dorsal columns) for the treatment of certain pain conditions. Spinal cord stimulation is a consideration for people who have a pain condition that has not responded to more conservative therapy. The spinal cord stimulation system consists of three components: the implanted pulse generator (IPG), the lead, and patient remote.
Precise quantities are unknown. It is anticipated that initial expenditure will be in the region of £21,000,000 to £25,000,000 in the first year of this framework agreement; however, this is approximate only and the values may vary depending on the requirements of those bodies purchasing under the framework agreement.
Dorsal root ganglion (DRG) therapy is a new type of neurostimulation therapy designed to manage difficult-to-treat chronic pain in specific areas of the lower body, such as the foot, knee, hip or groin. If you suffer from this kind of pain, DRG therapy may work where other therapies have not — or may have provided only partial relief. The dorsal root ganglion system consists of three components: the implanted pulse generator (IPG), the lead and patient remote.
Precise quantities are unknown. It is anticipated that initial expenditure will be in the region of £2,000,000 to £2,500,000 in the first year of this framework agreement; however, this is approximate only and the values may vary depending on the requirements of those bodies purchasing under the framework agreement.
The vagal nerve stimulation therapy system uses a surgically implanted medical device that delivers pulsed electrical signals to the vagus nerve. It is used as an adjunctive treatment for certain types of intractable epilepsy and treatment-resistant depression as well as other medical conditions. The vagal nerve stimulation system consists of three components: the implanted pulse generator (IPG), the lead and patient remote.
Precise quantities are unknown. It is anticipated that initial expenditure will be in the region of £6,000,000 to £7,200,000 in the first year of this framework agreement; however, this is approximate only and the values may vary depending on the requirements of those bodies purchasing under the framework agreement.
Peripheral nerve stimulation is a commonly used approach to treat chronic pain. It involves surgery that places a small electrical device (a wire-like electrode) next to one of the peripheral nerves.


Award value: 280000000